Report Detail

Medical Devices & Consumables China Oncology Biosimilars Market Report 2019

  • RnM3847199
  • |
  • 12 December, 2019
  • |
  • Global
  • |
  • 104 Pages
  • |
  • XYZResearch
  • |
  • Medical Devices & Consumables

In this report, our team research the China Oncology Biosimilars market by type, application, region and manufacturer 2014-2020 and forcast 2021-2026. For the region, type and application, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.

Geographically, this report split China into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Oncology Biosimilars for these regions, from 2014 to 2026 (forecast), including
South China
East China
Southwest China
Northeast China
North China
Central China
Northwest China

China Oncology Biosimilars market competition by top manufacturers/players, with Oncology Biosimilars sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Celltrion Inc.
Pfizer Inc.
Biocon
BIOCAD
Apotex Inc.
Dr. Reddy's Laboratories Ltd.
Sandoz International GmbH
Intas Pharmaceuticals Ltd.
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
G-CSF
Hematopoietic Agents
Monoclonal Antibodies

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Oncology Biosimilars for each application, including
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

If you have any special requirements, please let us know and we will offer you the report as you want.


Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Oncology Biosimilars Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 G-CSF (Volume)
      • 2.1.2 Hematopoietic Agents (Volume)
      • 2.1.3 Monoclonal Antibodies (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.2.1 G-CSF (Value)
      • 2.2.2 Hematopoietic Agents (Value)
      • 2.2.3 Monoclonal Antibodies (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Retail Pharmacies (Volume)
      • 3.1.2 Hospital Pharmacies (Volume)
      • 3.1.3 Online Pharmacies (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Celltrion Inc.
      • 4.1.1 Celltrion Inc. Profiles
      • 4.1.2 Celltrion Inc. Product Information
      • 4.1.3 Celltrion Inc. Oncology Biosimilars Business Performance
      • 4.1.4 Celltrion Inc. Oncology Biosimilars Business Development and Market Status
    • 4.2 Pfizer Inc.
      • 4.2.1 Pfizer Inc. Profiles
      • 4.2.2 Pfizer Inc. Product Information
      • 4.2.3 Pfizer Inc. Oncology Biosimilars Business Performance
      • 4.2.4 Pfizer Inc. Oncology Biosimilars Business Development and Market Status
    • 4.3 Biocon
      • 4.3.1 Biocon Profiles
      • 4.3.2 Biocon Product Information
      • 4.3.3 Biocon Oncology Biosimilars Business Performance
      • 4.3.4 Biocon Oncology Biosimilars Business Development and Market Status
    • 4.4 BIOCAD
      • 4.4.1 BIOCAD Profiles
      • 4.4.2 BIOCAD Product Information
      • 4.4.3 BIOCAD Oncology Biosimilars Business Performance
      • 4.4.4 BIOCAD Oncology Biosimilars Business Development and Market Status
    • 4.5 Apotex Inc.
      • 4.5.1 Apotex Inc. Profiles
      • 4.5.2 Apotex Inc. Product Information
      • 4.5.3 Apotex Inc. Oncology Biosimilars Business Performance
      • 4.5.4 Apotex Inc. Oncology Biosimilars Business Development and Market Status
    • 4.6 Dr. Reddy's Laboratories Ltd.
      • 4.6.1 Dr. Reddy's Laboratories Ltd. Profiles
      • 4.6.2 Dr. Reddy's Laboratories Ltd. Product Information
      • 4.6.3 Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Business Performance
      • 4.6.4 Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Business Development and Market Status
    • 4.7 Sandoz International GmbH
      • 4.7.1 Sandoz International GmbH Profiles
      • 4.7.2 Sandoz International GmbH Product Information
      • 4.7.3 Sandoz International GmbH Oncology Biosimilars Business Performance
      • 4.7.4 Sandoz International GmbH Oncology Biosimilars Business Development and Market Status
    • 4.8 Intas Pharmaceuticals Ltd.
      • 4.8.1 Intas Pharmaceuticals Ltd. Profiles
      • 4.8.2 Intas Pharmaceuticals Ltd. Product Information
      • 4.8.3 Intas Pharmaceuticals Ltd. Oncology Biosimilars Business Performance
      • 4.8.4 Intas Pharmaceuticals Ltd. Oncology Biosimilars Business Development and Market Status
    • 4.9 STADA Arzneimittel AG
      • 4.9.1 STADA Arzneimittel AG Profiles
      • 4.9.2 STADA Arzneimittel AG Product Information
      • 4.9.3 STADA Arzneimittel AG Oncology Biosimilars Business Performance
      • 4.9.4 STADA Arzneimittel AG Oncology Biosimilars Business Development and Market Status
    • 4.10 Teva Pharmaceutical Industries Ltd.
      • 4.10.1 Teva Pharmaceutical Industries Ltd. Profiles
      • 4.10.2 Teva Pharmaceutical Industries Ltd. Product Information
      • 4.10.3 Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Business Performance
      • 4.10.4 Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Business Development and Market Status

    5 Market Performance for Manufacturers

    • 5.1 China Oncology Biosimilars Sales (K Units) and Market Share by Manufacturers 2014-2020
    • 5.2 China Oncology Biosimilars Revenue (M USD) and Market Share by Manufacturers 2014-2020
    • 5.3 China Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
    • 5.4 China Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 South China Market Performance for Manufacturers
      • 6.1.1 South China Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.1.2 South China Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.1.3 South China Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.1.4 South China Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.1.5 Market Concentration
    • 6.2 East China Market Performance for Manufacturers
      • 6.2.1 East China Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.2.2 East China Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.2.3 East China Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.2.4 East China Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.2.5 Market Concentration
    • 6.3 Southwest China Market Performance for Manufacturers
      • 6.3.1 Southwest China Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.3.2 Southwest China Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.3.3 Southwest China Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.3.4 Southwest China Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.3.5 Market Concentration
    • 6.4 Northeast China Market Performance for Manufacturers
      • 6.4.1 Northeast China Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.4.2 Northeast China Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.4.3 Northeast China Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.4.4 Northeast China Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.4.5 Market Concentration
    • 6.5 North China Market Performance for Manufacturers
      • 6.5.1 North China Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.5.2 North China Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.5.3 North China Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.5.4 North China Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.5.5 Market Concentration
    • 6.6 Central China Market Performance for Manufacturers
      • 6.6.1 Central China Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.6.2 Central China Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.6.3 Central China Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.6.4 Central China Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.6.5 Market Concentration
    • 6.7 Northwest China Market Performance for Manufacturers
      • 6.7.1 Northwest China Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.7.2 Northwest China Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.7.3 Northwest China Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.7.4 Northwest China Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.7.5 Market Concentration

    7 China Oncology Biosimilars Market Performance (Sales Point)

    • 7.1 China Oncology Biosimilars Sales (K Units) and Market Share by Regions 2014-2020
    • 7.2 China Oncology Biosimilars Revenue (M USD) and Market Share by Regions 2014-2020
    • 7.3 China Oncology Biosimilars Price (USD/Unit) by Regions 2014-2020
    • 7.4 China Oncology Biosimilars Gross Margin by Regions 2014-2020

    8 Development Trend for Regions (Sales Point)

    • 8.1 China Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.2 South China Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.3 East China Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.4 Southwest China Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.5 Northeast China Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.6 North China Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.7 Central China Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.8 Northwest China Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate2014-2020

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Retail Pharmacies Industry
    • 11.2 Hospital Pharmacies Industry
    • 11.3 Online Pharmacies Industry

    12 Market Forecast 2021-2026

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
      • 12.1.1 China Oncology Biosimilars Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
      • 12.1.2 China Oncology Biosimilars Sales (K Units) and Growth Rate 2021-2026
      • 12.1.3 South China Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.4 East China Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.5 Southwest China Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.6 Northeast China Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.7 North China Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.8 Central China Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.9 Northwest China Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    • 12.2 Sales (K Units) and Revenue (M USD) Forecast by Types 2021-2026
      • 12.2.1 Overall Market Performance
      • 12.2.2 G-CSF
      • 12.2.3 Hematopoietic Agents
      • 12.2.4 Monoclonal Antibodies
    • 12.3 Sales and Growth Rate Forecast by Application 2021-2026
      • 12.3.1 Overall Market Performance
      • 12.3.2 Retail Pharmacies
      • 12.3.3 Hospital Pharmacies
      • 12.3.4 Online Pharmacies
    • 12.4 Price (USD/Unit) and Gross Profit Forecast
      • 12.4.1 China Oncology Biosimilars Price (USD/Unit) Trend 2021-2026
      • 12.4.2 China Oncology Biosimilars Gross Profit Trend 2021-2026

    13 Conclusion

    Summary:
    Get latest Market Research Reports on China Oncology Biosimilars . Industry analysis & Market Report on China Oncology Biosimilars is a syndicated market report, published as China Oncology Biosimilars Market Report 2019. It is complete Research Study and Industry Analysis of China Oncology Biosimilars market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,000.00
    $5,800.00
    2,319.00
    4,483.40
    2,793.00
    5,399.80
    458,070.00
    885,602.00
    253,200.00
    489,520.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report